Ratings Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
72.83 ^USD	-1.45%		+3.36%	+1.97%

08/04	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
03/04	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
With an expected P/E ratio at 43.52 and 25.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
LIGAND PHARMACEUTICALS INCORPORATED	+1.97%	1.31B	C-
ELI LILLY AND COMPANY	+31.52%	690B	C+
NOVO NORDISK A/S	+21.96%	546B	B
JOHNSON & JOHNSON	-5.21%	358B	C+
MERCK & CO., INC.	+17.02%	323B	B-
ABBVIE INC.	+5.01%	287B	C+
ASTRAZENECA PLC	+13.68%	235B	B+
NOVARTIS AG	+3.81%	199B	B-
ROCHE HOLDING AG	-10.63%	195B	A+
AMGEN INC.	+3.98%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes